Stock CDXS CODEXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Codexis, Inc.

Equities

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
3.92 USD +17.37% Intraday chart for Codexis, Inc. +47.37% +28.52%
02/05 Earnings Flash (CDXS) CODEXIS Posts Q1 Revenue $17.1M, vs. Street Est of $13.3M MT
02/05 Transcript : Codexis, Inc., Q1 2024 Earnings Call, May 02, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 935.7 1,388 2,029 306.1 213 276.6 - -
Enterprise Value (EV) 1 935.7 1,388 2,029 306.1 213 276.6 276.6 276.6
P/E ratio -76.1 x -54.6 x -94.8 x -9.14 x -2.72 x -6.7 x -5.67 x -
Yield - - - - - - - -
Capitalization / Revenue 13.7 x 20.1 x 19.4 x 2.21 x 3.04 x 4.25 x 4.49 x 3.38 x
EV / Revenue 13.7 x 20.1 x 19.4 x 2.21 x 3.04 x 4.25 x 4.49 x 3.38 x
EV / EBITDA -232 x -97.4 x -254 x -10.4 x -3.4 x -5.46 x -4.84 x -
EV / FCF -57.4 x -60.8 x -56.8 x -133 x -3.73 x -4.62 x -4.65 x -64 x
FCF Yield -1.74% -1.64% -1.76% -0.75% -26.8% -21.6% -21.5% -1.56%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 58,518 63,568 64,875 65,687 69,830 70,558 - -
Reference price 2 15.99 21.83 31.27 4.660 3.050 3.920 3.920 3.920
Announcement Date 27/02/20 25/02/21 24/02/22 23/02/23 28/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 68.46 69.06 104.8 138.6 70.14 65.15 61.61 81.85
EBITDA 1 -4.036 -14.24 -7.991 -29.48 -62.55 -50.7 -57.13 -
EBIT 1 -12.55 -23.92 -22.7 -34.88 -68.07 -57.11 -33.1 -
Operating Margin -18.33% -34.64% -21.67% -25.17% -97.04% -87.65% -53.72% -
Earnings before Tax (EBT) 1 -11.92 -23.67 -21.09 -33.32 -76.17 -53.71 -49.23 -
Net income 1 -11.94 -24.01 -21.28 -33.59 -76.24 -53.75 -49.25 -
Net margin -17.43% -34.77% -20.31% -24.24% -108.69% -82.5% -79.94% -
EPS 2 -0.2100 -0.4000 -0.3300 -0.5100 -1.120 -0.5850 -0.6917 -
Free Cash Flow 1 -16.29 -22.82 -35.69 -2.294 -57.06 -59.86 -59.54 -4.322
FCF margin -23.8% -33.04% -34.07% -1.66% -81.34% -91.87% -96.63% -5.28%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 27/02/20 25/02/21 24/02/22 23/02/23 28/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 36.77 24.5 35.34 38.41 34.47 30.38 12.98 21.32 9.277 26.56 17.07 8.342 15.23 25.34 12.13
EBITDA 1 -3.718 -6.369 -3.333 1.963 -4.7 -8.879 -19.39 -8.358 -27.29 1.498 -11.01 -18.19 -15.58 -6.295 -16.8
EBIT 1 1.33 -10.38 -8.386 -2.609 -10.64 -13.25 -23.66 -12.55 -32.06 0.282 -11.89 -16.86 -12.49 -11.36 -6.4
Operating Margin 3.62% -42.39% -23.73% -6.79% -30.86% -43.62% -182.29% -58.88% -345.59% 1.06% -69.63% -202.16% -81.99% -44.82% -52.77%
Earnings before Tax (EBT) 1 2.354 -10.12 -8.347 -2.532 -9.984 -12.45 -22.6 -11.51 -34.9 -7.157 -11.5 -18.85 -16.29 -7.079 -12.55
Net income 1 2.244 -10.19 -8.356 -2.64 -9.992 -12.6 -22.62 -11.52 -34.91 -7.192 -11.5 -18.86 -16.3 -7.089 -12.56
Net margin 6.1% -41.59% -23.64% -6.87% -28.99% -41.5% -174.22% -54.04% -376.29% -27.08% -67.39% -226.04% -107.01% -27.98% -103.55%
EPS 2 0.0300 -0.1600 -0.1300 -0.0400 -0.1500 -0.1900 -0.3400 -0.1700 -0.5000 -0.1000 -0.1600 -0.2186 -0.1743 -0.0617 -0.1633
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 04/11/21 24/02/22 05/05/22 04/08/22 03/11/22 23/02/23 04/05/23 03/08/23 02/11/23 28/02/24 02/05/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -16.3 -22.8 -35.7 -2.29 -57.1 -59.9 -59.5 -4.32
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share 2 - -0.2800 -0.1000 0.1700 -0.7700 -0.4100 - -
Capex 1 3.73 3.75 13.8 8.31 4.42 10 2.5 2.56
Capex / Sales 5.45% 5.43% 13.17% 5.99% 6.3% 15.35% 4.06% 3.13%
Announcement Date 27/02/20 25/02/21 24/02/22 23/02/23 28/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Codexis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.92 USD
Average target price
6.571 USD
Spread / Average Target
+67.64%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CODEXIS, INC. Stock Codexis, Inc.
+28.52% 277M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CDXS Stock
  4. Financials Codexis, Inc.